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REPRODUCIBILITY OF THE IMMUNOFLUORESCENT TEST FOR 
ANTIMELANOMA ANTIBODIES 
ELIZABETH A . ABEL, M.D .• AND JEAN-C LAUDE B VSTRVN, M.D. 
Department of Dermatology. Neu ' York Univen;it,\ School of M edicine. Neu' York , Neu' York. U. S. A . 
The reproducibilit y of the indirect immunofluorescent lest fo r ant ibodies to human 
malignant melanoma cytoplasmic antigens was investigated by testing panels of melanoma 
and normal sera against cells of each of several diffe rent melanomas. Tests were performed in 
replicate, read blindly by tWo observers. and repeated on different days. Different observers 
agreed in the interpretation of replicate assa~'s in app roximately 80 to 90% of cases. 
Variabilit y increased considerably when assays were repeated on different days or when 
different melanomas were used as substrate. Under these ci rcumstances. similar results were 
obtained in as few as 21 (~ of test. Thus. the results of the indirect immunofluorescent test for 
melanoma cytoplasmic antibodies must. at the present time. be interpreted with great 
caution. 
Humoral and cell ular immune responses to tu-
mor-8!,5<ociated antigens a re found to most animal 
and human tumors 1] -4 I. These immune responses 
are believed to playa major 15.6J. though complex 
171, role in host resistance to malignanc~·. 
One of the human malig-nancies in which the 
presence of humoral and cellular immunit~' to the 
tumor has been most extensi\·ely docume nt ed is 
mali~nant melanoma 18- 24\. Humoral antibodies 
to melanoma·associated anlig-e ns ha\'e been de-
tected by a number of techniques including in· 
direct immunofluorescence 18- J 61. cytotoxicity 
110.1.';.1 i . 19 J. radioart i\'e isotope uptake 120 J. im-
munop recipitatiol1 [211. immunoelectrophoresis 
1221. complement-dependent inhibition of R:\A 
syn th esis IIOJ. and the blocking of I)'mphoc),te-
mediated killing of tumor cell, 123.24 J. These 
antibodies are direct.ed to antigens. 011 the su rface 
and in the c~· toplasm of melanoma cells. It appears 
that cytoplasmic antigen~ are of similar specificity 
in many melanomas. \\'hereas !'urface ant igens ma~' 
be distinct in different melanomas 11O.2.1.26J. 
The incidence of antimelanoma antibodies in 
pat ients with melanoma and in normal persons 
varies greatl~' in different Rtudif's. as can be seen in 
Table I. Some of these differences may be due to 
the extent of the melanoma since there is eddenre 
that amimela noma antibodies are most frequent in 
localized disease and disappear as the tumor 
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progresses 11O.16.27J. though an opposi te trend has 
a lso been obsen 'ed 113.14J. The difference may 
also be due to problems with the reproducibili,,· of 
assays of melanoma antibodies. Such reproducibil· 
ity has not been in\'estigated systematically. 
The following study was conducted to determine 
the reproducibility of what is presently the most 
commonly used assay of antibodie~ to melanoma, 
i.e .. the indirett immunofluorescent test. The test 
for cytoplasmic rather than cell surfaC'e antibodies 
was chosen as cytoplasmiC' antibodies exhibi t 
cross· reacti\'ity with different melanomas. thus 
ob\' iating the need for autochthonou. tumor cells 
for each serum specimen tested. It was found that 
there was fai r agreement in the interpretation of 
the same test by different observers and of repli-
cate test s of t he same speci men . However. \'a riabil-
ity increased when tests were performed on differ-
ent days. and when different melanoma cel l lines 
were used a!' substrate . 
MATERJALS A)\D METHODS 
Sera 
Sera were obtained frnm 39 patients with malignant 
melanoma in different ~ tages; seen by the rVl elanoma 
Immunalog.\' Study Group at :'\ew York l ·niversit y. and 
from 21 normal blood bank donors . The diag"nosis. 
according to th«:> (,Iassification of Mihm et 81 [28J. was 
confirmed in every rasp by biops~'. Sera were stored at 
70°C In 0.1-0.:\ ml al iquOls and diluted 1:5 in phos· 
phatP.bufff'r(>d saline (PBS). pH 1.2. prior to us(> . 
Cell:. 
Sur~ically excil't"d melanoma cells were finely minced 
with scissors in a Petri dish in 5 ml of PBS . The resulting 
suspenl'ion WAS filtered through a 150-gaug:e stainless-
l'teel mesh. The ('ells were collec ted by centrifugation at 
500 I!. for 6 min. washed once with -'0 rnl of PBS. and 
resuspended in PBS at 8 concentration of 10' cells per mt. 
One drop of t he cell suspension was placed on three 
separate areas of each f:!;\ass slide. air dried for 30 min. 
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TABLE I. Summary of antimelanoma cytoplasm ic anribodies studies 
AUlhors 
Oettgen et 01, 1968 18) 
M orton et 01. 1968 19) 
Lewis et 01. 1969 110) 
Muno et 01, 1969111) 
Romsdohl et al. 1970 /12) 
Whitehouse, 1973 /13) 
W ood et a l. 1974 /14 ) 
Romsdohl et 01. 1970112) 
Morton et 01. 196819) 
Nai rn e l al. 1972 (15j 
Bourgoin el 81. 1972116] 
Wood et al. 19741141 
Source or tumor celts 
Tissue culture (Tel 
Tumor imprint (Tl) 
TC 
TC 
TI 
TC 
Cryostat-cut tumor 
TI 
TI 
TI 
Fresh ce ll suspension 
TC/ fresh cell suspension 
TI 
II Number of sera t,ested in parenthese~ . 
fixed in 8cetone for 10 min, and sto red in a Revco freeze r 
8t _ 70 De. 
Alternati\'ely, cryosta t ·cut sections of freshly excised 
tumor tissue were frozen in liquid nitrogen. placed in 
embeddin~ media fOT.T . compou nd. Tissue·Tek, Ames 
Co .. Elkhart. Ind iana) at - 20 D C and cut in 4-p sect ions. 
Imm unofluorescent Tes( 
Indirect immunon uorescent (IF ) tests were performed 
by a standardized technique 1'291 as pn!\'inusly descr ibed 
[30]. The conjugate was fluorescein· labeled goat antihu-
man H and L chain. obtai ned from a commercial source 
(Hyla nd Co .. Costa Mesa, Calif. I. This conjUf,!8te reacted 
specifically to human 19G and I!!M b:,>' immunoelectro· 
phoresis . The protein concentration was 24 mg-Jml. the 
antibody content 1.6 mg/ m!. the nuorescein isothiocya. 
nate concentra t ion 0.166 mg/ m!. and the OU(lrescein to 
protein ratio 6.9 mg/~m . FQr use . the <:onjugate was 
dilut ed 1:32 in PBS . The slides we re examined with a 
Zeiss binocular mic roscope equipped with an HRO mer· 
cury vapor lamp and with a Zeiss FITe exciter and "50" 
barr ier filte rs. One to two hundred cells were count ed at 
312, and t hose fluorescing a bri)!ht apple.!!reen were 
graded positi\'e, as contrasted to the dull green. nonspe-
cific staini ng of negat ive reactions. Sera g:iv inJ! ell lea~t 
30Q; more positin tells than a norm al cont ro l serum were 
considered pos it ive fo r anti melanoma anti bodies. This 
pe rcentage was selected arbit rarily. The pertentag:e of 
nuoresci ng cel ls required for seropositivity by prior inves· 
t igators has rang:ed from 3(:( to " most." In general, 
pos it ive se ra s tained over 80 to 90 ('( of cells. while 
nega ti\."e sera stained Jess than 20ft. A greater difficulty 
was the evaluation of i1uorescence wh ich was d ull , hu t 
s till greater than that of the negative control. Such tests 
were read ao; plus/ minus and excluded from fu rther 
analys is. In addition to no rmal sera. the foll owing con -
t.rol s were used: ( I ) PBS , (2) ANA (antinuclear ant ibody· 
positive serum . and (3) serB which we had previous ly 
found to be pos it ive for melanoma cytopl asmic anti -
bodies. 
Fixation 
Acetone 
AcelOne 
Liquid N" 
Ethyl ,alc::ohol 
Acetone 
Acetone 
Liquid N, 
Ace tone 
Acetone 
Acetone 
Air dripd 
Liquid :\ 2 
Acetone 
Incidence of onlimelnnoma a.ntibQdi~~ 
ill person with : 
Mehllloma Other 
cancers 
A/luJ!em,jc Tumor Celt.~ 
GI C;{ (23 )" 
6] 1''; ( 134) 
37'1\ (471 
100"1 115) 
66c;t (231) 
52~ (251 
58'1\ (40) 
42'1< 1481 
10% (64) 
0'" (19\ 
0 1; (9) 
Aulo!O}!OUI> Tum or Cell,~ 
100% t i l 
100<;< 181 
27C1 (521 
38'; (601 
63fii ~8\ 
RESULTS 
Normul 
0% 181 
20<;; (125) 
0,", 112) 
O'~ 1221 
22'!l 1153) 
:JOO/C \ 10) 
2e, (131 
36«< (65) 
In itial experiment s were conducted to determine 
the v ariabilit)' of the indirect IF test for melanoma 
cj..-toplasm i(' a ntibodies \"'hen performed in repli· 
ca te. A panel of 7 different melanoma ~e ra \\'as 
reacted in quad ruplicaie again ::; t a !;: ingle ac'elOn e · 
fixed suspension of fresh ly excised mela noma celts. 
The s lides were read without knowledge of o r igin of 
the material by two obsen ·ers. The results a re 
s ummarized in Tahle II. Ten of the 28 s lides were 
read as plus/ mi nus and excluded from analysis . 
Both investigators read 1-1 of the rem a ining 18 
51 ides ((BCt 1 in the same manner. A l Ot a1 of' 56 
individual readings were made by both in\'est iga-
tors, of which 1:1 we re plus/minu~ and excluded 
from further analysis. Th irty·seven of the remain-
ing 43 readings (86 Of ) agreed with th e average 
reading fo r that !Oerum. Howe\'er. in -1 of' t he i sera 
te5ted . one investigator read at least I of 1 he 
quadruplicate s lides differently from the a\'e rage 
reading fo r that seru m. In anot her study, JO 
melano ma and 10 norm al sera 'were test ed in 
duplicate against the sa me cell !' and read wi thou t 
kn owledge of or i~ in of the materia l by bot h observ. 
e rs. Of the resu lt ing 40 slides. :\8 (95"; \ were read in 
the same m an ne r b)' both investigators. The read-
ing of duplica t.e s lides of the same SerB was s imilar 
in 18 of the 20 specimens (90%). Simila r results were 
o btained in several other experiments of t h is type . 
T o determine the variabil ity o f' Les t s perform ed 
on different days. three experim ents were con· 
duct.ed in which panels of 14. 19. and 23 sera. 
respect.i ve ly, were reacted on 2 different d ays 
against the sa me preparation of melanom a cells. 
Similar resul ts were o btained on both days in 80%, 
800/c, and 74 % of cases, res pectively. Va riabilit y of 
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resu lts increased as the test was repeated more 
frequently . Table III illustrates t he reproducibility 
of results when a panel of 10 melanoma and 10 
normal sera was tested on 3 different days against 
the same melanoma cells. Excluding slides read as 
plus/minus, identical results were obtained on all 3 
days with only 10 of the 20 (50%) sera tested. 
To determine the effect of the melanom a cells 
used as substrate on the results of the test. a panel 
of 33 melanoma and 20 normal sera was tested 
aga inst acetone· fixed cell suspensions prepared 
from 3 different melanoma and against cryostat-
cut sections of fresh tumor tissue from 2 of th ese 
tumors. As can be seen jn Table IV . the overa ll 
incidence of pos itive reactions was influenced by 
the melanoma used and by the manner affixation. 
A higher incidence of pos itive reactions with both 
norm al and melanoma sera was observed wit h 
cryost at -cut sections. Presence of melanoma-
assoc iated antigens. as suggested by a stat.ist ically 
s ignificantly greater incidence of anlicytoplasmic 
antibodies in melanoma sera t han in norm al sera 
(p < 0.05) was present in only 1 of the 5 subsirates 
tes ted (HM -8. cryos tat-cu t ). Looking only at the 
results obtained with this substrate. the incidence 
of ant ibod ies to the cytoplasm of melanoma cells 
was 61 % in the panel of sera of patients with 
mel anoma and 259, in norm al persons. In only 11 of 
53 (21 ~ ) instances did the same serum give ident i-
ca l results with a ll 5 substrates . 
Since it has been reported that the incidence of 
cytoplasmic ant ibodies t o melanoma varies with 
the extent of tumor. the results obtained with the 
one subst rate (HM -8 . cryost.at-cut) which ap-
peared to con tain melanoma-associated antigens. 
were correlated \'.li th the stage of disease. Melano-
mas were staged in 32 of the abo,·e 33 patients 
according- to t he followi ng classifications: stage 
I-local tumor. no node involvement: stage II-re-
gional node invol\'ement: and sta t.e IlI-s~'stemic 
metastasis. As can be seen in Table Y. there was no 
T ABLE II. Reproducibillt.\ of immunofluorescentt€srs {or 
antimelanoma cytoplasmic antibodies performed in 
quadrupiicatp and interpreted by tu 'O different 
InU€stlpotors 
Anlimelanoma antibodies 
Sera Sl ide I Slide 11 Slide III Slide 1\' 
s" b" s " b" s" b" s" b" 
113 T T + + + T T 
156 + + ± ± 
192 + 
163 + ± ± ± ± ± 
128 ± ± ± 
145 ± ± ± 
946 
PBS' 
" Readings of two separat.e investigator? 
" Phosphate· buffered saline. 
TABLE il1. Reprodu cibility of immunofluorescent tests for 
antimelanoma cytoplasmic antibodies performed on 
different da.vs 
Antimelanoma an tibodies-Date of assay 
Sera 
t /10 4/25 5/2 
Melanoma 
127 + + 
139 
148 ..- + 
156 + + 
173 T 
174 + 
181 T 
437 T 
340 T 
192 
1\'ormal 
2823 T 
2861 ± 
2870 
287 1 
2872 
2874 
2878 
2880 
2882 
2865 
PBS 
TABLE J\' . In cidence of onrimelanoma antibodies in 
melanoma and normal sera tested against different 
substrates 
~ Antimelanoma antibodies I ~ sera tested I 
n ' ___ __ ,_ I ~o. 
Diagnosis sera A('ewne-fixed Cryoslat -CUI 
tesled melanoma melanomll 
L----~---.----------,---­
HM·; I HM.s l HM ·IO HM ·S IHM.IO 
Melanoma 33 36 
20 
3 
10 
61 51 
~ 5 Nor mal 20 
p. 0.5- 0.1 \'S" 
"Chi square test. 
b 1\'ot significant. 
:\S 
correlat ion bet ween t.he extent of melanoma a nd 
the incidence of anticytoplasmic antibodies. 
DISCUSSION 
in th is study different observers agreed on the 
interpretation of replicate indirect immunofl uores-
cent tests for ant imelanoma cytoplasmic anti-
bodies in approximately 80 to 90 % of cases. Varia-
bility of the assay was considerably greater when 
repeated on successive days (agreement in 50l?t of 
tests) or when diffe rent melanoma cells were used 
as substrate (agreement in 21 % of tests). With only 
1 of 5 melanoma substrates was a significant 
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TABl.£ V . Incidence of antim elanoma ant ibodies l 'S stage 
of ma lil!nan r m elanoma 
Nt). Df Anl irneianmna a nt ibodies StBJ!:e(lf pat ients :--.10. of t; of melanoma 
stud ied pBtients patient s 
I 23 12 52 
II 3 3 100 
III 6 5 8:l 
Normal controls 20 5 9 -_ 0 
differen ce obtained in the incidence of a n· 
timelanoma cytoplasmk' ant ibodies in persons 
with melanoma as compared to normal controls . 
There was no correlat ion bet ween the st age of the 
melanom a and the incidence of melanoma ant j . 
bodies_ 
It is recolWized tha t a number of technical 
factors may influence the res:.l lts of the indiret' t 
immunofluorescent test s for melanoma ant ibodies 
114 J. These incl ude the type of microsco pe. l i~ht 
source and filter system: the source and fiX8 \ ion of 
target cells: the source. specifi ci ty. and dilution of 
the conjugate: the method of preparation. storaJ!e 
and d ilut ion of serum : and the cr iteri a used t o 
determine posith·ity. Th is st.udy indicates tha t 
even when these fa ctors are controlled . there is s t ill 
co nsiderabl e \'aria t ion in results of the tes t. This 
va riability reflects. in part. the subjective nature of 
interpreting- brig-htness of flu orescen ce. ev en 
though an effort was made to reduce this source of 
error by excluding from anal ysis all equivocal 
(~ /- ) results . Further studies have to be done 10 
determine other fac tors wh ich may contr ibute t.o 
variability. 
The summation of the error in reproducib ility of 
replicate assays performed on the same day can 
account for most of the variabil ity observed when 
the tesl is performed on different days or againsl 
different substrates. Thus. some or all of Ihe 
differences in cross·reactiv ities observed in this 
and olher studies 114-16J. when panels of mela-
noma sera are tested against different mel a nomas. 
may be due to variability of the tesl rather than. as 
commonly believed. to differences in the amount 
and/or specifici ty of melanoma·associated anti· 
gens. In general. little is known aboUl qu a litati\'e 
and quantitative d ifferen ces in tumor-associated 
antigens in different melanomas. Furthermore. the 
frequency and cond itions under which these a nti -
gens stimulate antibody synthesis have not been 
determined . These factors will also undoubtedly 
influence the results of antimelanoma antibody 
tests. 
Another difficulty in interpreting Ihe s ignifi-
cance of ant imelanoma cytoplasmic antibodies is 
the frequent presen ce of ant.ibodies binding to the 
cywplasm of melanoma cells in normal persons, as 
can be seen from our results as well as from Table I 
which summarizes the studies of other investiga . 
tors. Wood and Barth have shown that such 
antibodies may be as frequent in normal persons as 
Vol. 66. No. 2 
in patients with melanoma, though the titer may 
be si~nificantly greater in the latter group [14 I. 
The causes for positive antimelanoma antibody 
tests in. persons without melanoma are not clear 
but probably include technical problems with the 
test as well 8S the presence in normal persons of 
antibodies to melanocyte and/or epidermal anti-
gens which may also be present in melanoma cells. 
The occurrence of immune responses to antigens 
in normal melanocytes which may cross· react or 
be immunologically identical with melanoma-asso-
ciated antigens is suggested by the killing of 
melanoma cells by lymphocytes of normal Ameri-
can Blacks 131 J. and by antibodies to melanoma in 
otherwise healthy persons with halo nevi [32 ]. 
Conversely, there is evidence that persons with 
melanoma may form antibodies to normal tissue 
antigens or to antigens present in unrelated 
tumors. Thus, patients with melanoma may have 
antibodies to normal human epidermal 130J and 
fetal ant igens 113 J, or to antigens in unrelated 
malignancies 114 J. Furl.hermore. anti melanoma 
antibodies can be absorbed out with normal pig-
mented or nonpigmented human skin 1101. liver 
115J. or tissue from unrelated malignancies 114, 
15 J. 
The variability in results of indirect IF tests for 
a ntim elanoma c.vt opl asm ic an tibodies indi cates 
that. at the present time a great deal o f caution 
must be used in the interpreta t ion of th is assay. 
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